Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary. The pharmacokinetic (PK) response to factor VIII (FVIII) and factor IX varies between patients and this has important clinical implications for treatment. Although PK is affected by patient characteristics, this relationship is too weak to infer a result for an individual and, if required, PK must be measured. An important determinant of the efficacy of prophylaxis is the length of time an individual spends with a low level of coagulation factor. This time is more dependent on the patient’s coagulation factor half‐life and the frequency of dosing than in vivo recovery and dose infused. Improved understanding of the effect of PK and dose frequency on factor levels in patients on prophylaxis will help tailor regimens to individuals better and allow more cost effective use of coagulation factor concentrates. Calculations suggest that adults need less FVIII per kg body weight than children. The effect of half‐life on trough levels questions the logic of Monday, Wednesday, Friday dosing and suggests a role for innovative regimens including low‐dose daily treatment which leads to either higher trough levels or decreased FVIII requirement. This may expand access to prophylaxis in healthcare systems with limited resources and potentially improve patient outcomes. The ideal trough level will vary between individuals and at different times of their lives and may be <1 IU dL−1. If PK is to be used in routine clinical practice, a simplified method for its measurement is required and this methodology is becoming available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Cited by
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
Self-citationUchida, N., Sambe, T., Yoneyama, K., Fukazawa, N., Kawanishi, T., Kobayashi, S., & Shima, M. (2016) · Blood · doi:10.1182/blood-2015-06-650226 · Cited by 260
Transition considerations for extended half-life factor products
Croteau, S. E., & Neufeld, E. J. (2015) · Haemophilia · doi:10.1111/hae.12683 · Cited by 19
Metadata
- Authors
- COLLINS, P. W., FISCHER, K., MORFINI, M., BLANCHETTE, V. S., BJÖRKMAN, S., & ON BEHALF OF INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) PHARMACOKINETICS EXPERT WORKING GROUP
- Venue
- Haemophilia
- Publisher
- Wiley
- Published
- 2010-08-22
- Volume
- 17
- Issue
- 1
- Pages
- 2-10
- ISSN
- 1351-8216 (ISSN-L)
- 1365-2516
- OpenAlex
- W1895185717
- Cited by
- 200
- References
- 1
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. https://app.cochat.ai/papers/10.1111/j.1365-2516.2010.02370.x
- The paper
- COLLINS, P. W., FISCHER, K., MORFINI, M., BLANCHETTE, V. S., BJÖRKMAN, S., & ON BEHALF OF INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) PHARMACOKINETICS EXPERT WORKING GROUP. (2011). Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. https://doi.org/10.1111/j.1365-2516.2010.02370.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.